Creating Value In Pharma-Health Plan Collaborations
Executive Summary
A wave of research-based collaborations between pharmaceutical companies and payors is enabling a new level of credibility, trust, and joint efforts to enhance patient care.
You may also be interested in...
New Insurance Marketplaces Won’t ‘Move The Needle’ Near-Term For Pharma Economics – An Interview With Booz & Co.
Jan. 1, 2014, the date insurance coverage expansion begins, is a key marker in the implementation of the Affordable Care Act, but experts, including Booz & Co. partners Elizabeth Powers and Greg Rotz say it isn’t likely to have a big near-term impact on drug manufacturers. Initial enrollment into health insurance exchanges and expanded Medicaid programs is expected to be limited, benefit plan designs are still unknown, and many uncertainties remain.
AZ, IMS To Build Disparate Data Sets Into Broader Outcomes Consensus
Individual deals with payers or information providers won’t provide pharma with the breadth of outcomes data they need to secure reimbursement for their drugs. A far broader stakeholder consensus is required.
AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions
Accessing IMS Health’s European electronic health records and jointly building a customized data analysis platform will inform AstraZeneca’s R&D priorities and support outcomes claims of newly-launched drugs.